Zacks: Analysts Expect uniQure N.V. (QURE) Will Announce Earnings of -$0.80 Per Share
Equities analysts expect uniQure N.V. (NASDAQ:QURE) to post earnings per share (EPS) of ($0.80) for the current quarter, Zacks reports. Two analysts have made estimates for uniQure N.V.’s earnings. The lowest EPS estimate is ($0.85) and the highest is ($0.70). uniQure N.V. posted earnings per share of ($0.60) in the same quarter last year, which would indicate a negative year over year growth rate of 33.3%. The firm is scheduled to announce its next earnings report on Tuesday, November 28th.
On average, analysts expect that uniQure N.V. will report full-year earnings of ($3.14) per share for the current year, with EPS estimates ranging from ($3.34) to ($2.93). For the next fiscal year, analysts forecast that the company will report earnings of ($2.77) per share, with EPS estimates ranging from ($3.13) to ($2.32). Zacks’ earnings per share averages are an average based on a survey of research analysts that follow uniQure N.V..
uniQure N.V. (NASDAQ:QURE) last released its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.83) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.78) by $0.05. The firm had revenue of $4.94 million for the quarter, compared to analyst estimates of $2.92 million. uniQure N.V. had a negative return on equity of 131.27% and a negative net margin of 289.94%.
Several research firms recently commented on QURE. ValuEngine upgraded uniQure N.V. from a “sell” rating to a “hold” rating in a research note on Monday, July 24th. Zacks Investment Research upgraded uniQure N.V. from a “sell” rating to a “hold” rating and set a $9.25 price objective on the stock in a research note on Wednesday, August 9th. Chardan Capital set a $13.00 price objective on uniQure N.V. and gave the company a “buy” rating in a research note on Sunday, July 23rd. Oppenheimer Holdings, Inc. reiterated an “outperform” rating and issued a $17.00 price objective on shares of uniQure N.V. in a research note on Friday, June 30th. Finally, Cowen and Company reiterated a “buy” rating on shares of uniQure N.V. in a research note on Wednesday, May 24th. One research analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $12.45.
uniQure N.V. (NASDAQ QURE) traded down 1.42% during mid-day trading on Friday, reaching $8.36. The company had a trading volume of 86,014 shares. uniQure N.V. has a one year low of $4.72 and a one year high of $9.15. The stock’s market capitalization is $213.68 million. The company’s 50-day moving average is $8.25 and its 200-day moving average is $6.37.
In other uniQure N.V. news, insider Harald Petry sold 49,300 shares of the stock in a transaction on Thursday, June 29th. The stock was sold at an average price of $6.02, for a total transaction of $296,786.00. Following the sale, the insider now owns 27,753 shares in the company, valued at $167,073.06. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 173,460 shares of company stock worth $1,042,986. Company insiders own 0.73% of the company’s stock.
Several large investors have recently bought and sold shares of QURE. Oxford Asset Management purchased a new stake in shares of uniQure N.V. during the first quarter worth $100,000. Mangrove Partners purchased a new stake in shares of uniQure N.V. during the second quarter worth $247,000. JPMorgan Chase & Co. lifted its position in shares of uniQure N.V. by 50.5% during the first quarter. JPMorgan Chase & Co. now owns 43,822 shares of the biotechnology company’s stock worth $253,000 after acquiring an additional 14,702 shares in the last quarter. Weiss Multi Strategy Advisers LLC lifted its position in shares of uniQure N.V. by 266.7% during the first quarter. Weiss Multi Strategy Advisers LLC now owns 55,000 shares of the biotechnology company’s stock worth $318,000 after acquiring an additional 40,000 shares in the last quarter. Finally, Paloma Partners Management Co lifted its position in shares of uniQure N.V. by 717.7% during the first quarter. Paloma Partners Management Co now owns 85,000 shares of the biotechnology company’s stock worth $491,000 after acquiring an additional 74,605 shares in the last quarter. Hedge funds and other institutional investors own 29.86% of the company’s stock.
About uniQure N.V.
Uniqure NV is a gene therapy company based in the Netherlands. The Company is engaged in the discovery, development and commercialization of single treatments with curative results for patients suffering from genetic and other severe diseases. The Company advances a focused pipeline of gene therapies that are developed both internally and through partnerships.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for uniQure N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure N.V. and related companies with MarketBeat.com's FREE daily email newsletter.